MedTrace Logo

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

Conditions

  • Sleep
  • Alzheimer Disease

Interventions

DRUG

Suvorexant 20 mg

Suvorexant 20mg will be taken nightly for 24 months.

DRUG

Placebo

Placebo will be taken nightly for 24 months.

Sponsors & Collaborators

  • Good Ventures

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Brendan Lucey, MD · Washington Univeristy School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04629547 on ClinicalTrials.gov